Welcome to our dedicated page for Macrogenics SEC filings (Ticker: MGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MacroGenics, Inc. (MGNX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. MacroGenics states that it is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer, and its filings offer additional detail on this business through formal reports.
Recent Forms 8‑K filed by MacroGenics include items on quarterly financial and operating results, as well as leadership changes. For example, the company has filed current reports describing results of operations and financial condition for specific quarters and announcing the appointment of a new President and Chief Executive Officer. Another Form 8‑K discloses the planned departure of the Senior Vice President, Clinical Development and Chief Medical Officer and notes interim oversight arrangements for clinical development.
Through this page, users can review MacroGenics’ current reports alongside other SEC documents such as annual and quarterly reports when available. These filings often reference press releases that discuss clinical programs like lorigerlimab, antibody-drug conjugate candidates MGC026, MGC028 and MGC030, and partnered programs including MGD024, ZYNYZ® and TZIELD®, as well as collaboration and royalty structures described by the company.
Stock Titan enhances access to these materials with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand the main topics in MacroGenics’ disclosures. Investors researching MGNX can use this page to follow official information on financial performance, executive transitions, material agreements and other events that MacroGenics reports to regulators.
MacroGenics Inc. insider activity: Sr VP, Research & CSO Ezio Bonvini reported routine equity transactions on February 7 and 8, 2026 involving restricted stock units (RSUs) and common stock of MacroGenics Inc. (MGNX).
On February 7, RSUs converting on a one-for-one basis were exercised for 7,001 shares of common stock, increasing his directly held common stock to 131,415 shares, while 2,703 shares were withheld at a price of $1.81 per share, leaving 128,712 shares directly owned. On February 8, an additional 11,166 RSUs were exercised into common stock, bringing direct common stock holdings to 139,878 shares before 4,311 shares were withheld at $1.81 per share, resulting in 135,567 directly owned common shares.
Following these transactions, Bonvini also held 13,999 RSUs from a February 7, 2025 grant of 21,000 RSUs vesting in three equal installments and 11,166 RSUs from a February 8, 2024 grant of 33,500 RSUs, also vesting in three equal installments beginning on the first anniversary of each grant date.
MacroGenics, Inc. announced that Stephen Eck, M.D., Ph.D., its Senior Vice President, Clinical Development and Chief Medical Officer, will depart the company effective December 31, 2025, following a mutual agreement reached on November 14, 2025. Oversight of clinical development will be handled on an interim basis by Frank Perabo, M.D., Ph.D., Vice President, Clinical Development, while an executive recruiter conducts a search for a new Chief Medical Officer. Dr. Eck, who joined MacroGenics in July 2020 and led clinical development across multiple studies, will receive payments and benefits for a qualifying termination in accordance with his employment agreement, conditioned on a general release, waiver of claims, and compliance with his restrictive covenants.
MacroGenics (MGNX) reported that it announced financial and operating results for the quarter ended September 30, 2025. The company furnished a detailed press release as Exhibit 99.1 to this Form 8-K. The information in this report, including Exhibit 99.1, is provided as “furnished” under the Exchange Act and is not deemed “filed.”
MacroGenics, Inc. reported Q3 results showing total revenue of $72.8 million versus $110.7 million a year ago, reflecting lower milestone revenue, partly offset by stronger contract manufacturing. Contract manufacturing revenue rose to $19.8 million from $4.6 million. Research and development expense declined to $32.7 million from $40.5 million.
The company generated quarterly net income of $16.8 million (basic and diluted EPS $0.27), compared with $56.3 million last year. Year to date, it recorded a net loss of $60.5 million as operating cash outflows reached $124.1 million. Cash and cash equivalents were $80.1 million with marketable securities of $66.3 million. Stockholders’ equity was $67.0 million.
In June, MacroGenics sold future ZYNYZ royalties to Sagard for $70.0 million, recognizing a liability of $70.3 million with an estimated effective interest rate of 18.6% and booked $3.3 million non-cash interest in Q3. It also recognized $50.0 million from two Sanofi regulatory milestones, included in accounts receivable at quarter end. Subsequent to quarter end, Gilead nominated a second research program and exercised its option, obligating a total of $25.0 million. Shares outstanding were 63,258,532 as of November 7, 2025. Management cites a cash runway into late 2027.
William K. Heiden, a director of MacroGenics, Inc. (MGNX), reported two open-market purchases of the company's common stock. On 08/19/2025 he purchased 50,500 shares at aggregate prices reported as $1.52 with trade prices in a range of $1.48 to $1.59, bringing his direct beneficial ownership to 61,500 shares. On 08/20/2025 he purchased an additional 49,500 shares at an aggregate price reported as $1.49 with trade prices in a range of $1.46 to $1.50, increasing his direct beneficial ownership to 111,000 shares. The Form 4 was signed by attorney-in-fact Beth A. Smith on 08/21/2025.
Thomas Spitznagel, Sr. VP Technical Ops at MacroGenics, Inc. (MGNX), acquired 30,000 shares of common stock through the exercise of employee stock options on 08/15/2025. The options had an exercise price of $1.58 and convert to 30,000 shares upon exercise. After the reported transaction, 30,000 shares are beneficially owned directly. The option grant vests 25% one year after the grant date with the remaining 75% vesting in 12 substantially equal quarterly installments thereafter. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
MacroGenics insider award: Senior Vice President and General Counsel Jeffrey Stuart Peters received an employee stock option grant for 30,000 shares on 08/15/2025. The option has an exercise price of $1.58, vests 25% after one year with the remaining 75% vesting in 12 substantially equal quarterly installments, and expires on 08/15/2035. Following the reported transaction Mr. Peters beneficially owns 30,000 common shares subject to the option on a direct basis. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
Scott Koenig, a director of MacroGenics, Inc. (MGNX), reported vested restricted stock units (RSUs) on 08/13/2025 that converted into common stock. The Form 4 shows two separate RSU vesting transactions under code M, totaling 52,829 RSUs (21,165 and 31,664) with a reported price of $0 per unit because each RSU represents a contingent right to one share. The filing states these vestings occurred pursuant to a Separation and Consulting Agreement that caused 50% of each outstanding unvested RSU to vest, and that vested shares will be delivered as soon as practicable. The Form is signed by an attorney-in-fact on 08/15/2025. The reported beneficial ownership figures following the transactions are shown as 798,580 and 830,244 shares on the two reporting lines.
Insider option grant to CEO/Director MacroGenics reported that Eric Blasius Risser, who serves as President and CEO and a director, was granted an employee stock option covering 550,000 shares of common stock with an exercise price of $1.66. The option was granted with an exercise schedule that vests 25% one year after grant and the remaining 75% in 12 substantially equal quarterly installments thereafter. The options are exercisable through 08/13/2035 and are directly owned by the reporting person following the transaction.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 5,960,000 shares of MacroGenics, Inc. (MGNX), equal to 9.45% of the outstanding common stock based on 63,090,323 shares outstanding as of May 9, 2025. The filing discloses that Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd. (the Master Fund), and Mr. Boyd, as managing member of Armistice Capital, each have shared voting and shared dispositive power over these shares and hold no sole voting or dispositive power. The Master Fund is the direct holder and retains the right to receive dividends or sale proceeds. This is an amendment (No. 5) to the Schedule 13G filed with the SEC.